416
Participants
Start Date
November 29, 2024
Primary Completion Date
June 1, 2027
Study Completion Date
December 1, 2027
PCSK9 inhibitors combined with atorvastatin/rosuvastatin
A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
Atorvastatin/Rosuvastatin
Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The Third People's Hospital of Hubei Province
OTHER
Hubei Shiyan People's Hospital
UNKNOWN
Yichang Central People's Hospital
OTHER
The Fifth Hospital of Wuhan
OTHER
Shanghai Zhongshan Hospital
OTHER
Renmin Hospital of Wuhan University
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Wuhan Third Hospital
OTHER
Taihe Hospital
OTHER
Suizhou Hospital, Hubei University of Medicine
UNKNOWN
Hubei Xinhua Hospital
OTHER
Tianyou Hospital Affiliated to Wuhan University of Science and Technology
OTHER
Minda Hospital Affiliated to Hubei University for Nationalities
UNKNOWN
Xiang Luo
OTHER